title: [Efficacy and safety of transfusion therapy in hematological patients].
abstract: OBJECTIVE
  To determine whether probability of hepatitis B and C virus (HBV/HCV) infection of hematological patients depends on intensity of hemotransfusion therapy and to propose possible ways to diminish posttransfusion risk of virus infection with HBV/HCV. MATERIAL AND METHODS; A clinicoepidemiological prospective trial was made to monitor risk factors and indicators of HBV and HCV infection in 216 patients of a hematological department of the Hematological Research Center. A total of 447 hospitalizations (229 rehospitalizations among them) to the department of chemotherapy, depression of hemopoiesis and bone marrow transplantation for 2 years were analysed. Statistics were analysed using SAS computer programs and the "landmark method".
  
  
  RESULTS
  Transfusions of blood components before initiation of the trial were performed in 201 (93%) patients, 120 (60%) patients received more than one transfusion (median of the number of donors was 40). Markers of virus hepatitis were initially detected 1 month after hospitalization in 103 (47.7%) patients: HCV--in 26 (12%), HBV--in 77 (35.6%); 18 (17.5%) patients were coinfected (HBV/ HCV). Probability of detection of HBV and HCV markers in patients with multiple transfusions was significantly higher than in patients with a short transfusion history (50% probability of HBV and HCV infection was 153 and 251 days, respectively, p = 0.059).
  
  
  CONCLUSIONS
  Reduction of aftertreatment lethality and, finally, treatment efficacy in hematological patients depends on adequacy of replacement therapy with blood components, platelets first of all. High percentage of HBV and HCV infection confirms dependence of infection probability on the number of donors. Thus, patients with planned massive replacement therapy should be provided with specially selected donors. Blood for transfusion for them should be examined for viruses repeatedly.
authors.forename: V G
authors.initials: VG
authors.lastname: Savchenko
authors.forename: T Ts
authors.initials: TTs
authors.lastname: Garmaeva
authors.forename: S M
authors.initials: SM
authors.lastname: Kulikov
authors.forename: F P
authors.initials: FP
authors.lastname: Filatov
authors.forename: A B
authors.initials: AB
authors.lastname: Sudarikov
authors.forename: E A
authors.initials: EA
authors.lastname: Mikhaĭlova
mesh_terms: D015415:Biomarkers / Q000097:blood; D005260:Female; D006402:Hematologic Diseases / Q000401:mortality / Q000628:therapy*; D016174:Hepacivirus / Q000276:immunology / Q000302:isolation & purification; D006509:Hepatitis B / Q000453:epidemiology / Q000209:etiology; D006515:Hepatitis B virus / Q000276:immunology / Q000302:isolation & purification; D006526:Hepatitis C / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D015994:Incidence; D008297:Male; D011446:Prospective Studies; D012307:Risk Factors; D065227:Transfusion Reaction
chemical_list: D015415:Biomarkers